Our purpose was to study the risk factors associated with disease progression after high-dose chemotherapy followed by autologous stem cell transplantation in patients with recurrent or refractory Hodgkin's lymphoma (HL). We analyzed the long-term outcome of 184 patients with recurrent or refractory HL who underwent autologous hematopoietic stem cell transplantation. At the time of transplantation, 82 patients were in first relapse or second remission, 46 patients were refractory to the primary induction chemotherapy, and 56 patients were beyond first relapse or second remission. In 64 patients, the disease had proved refractory to the chemotherapy regimen administered immediately prior to transplantation. The median follow-up of patients who were alive and free of disease at the time of this report was 8.9 years (range, 0.1-19.0 years). At 10 years, the overall and disease-free survival rates were 34% (95% CI 27-42) and 29% (95% CI 22-36) respectively. The major cause of treatment failure was disease relapse. Chemotherapy resistance prior to transplantation, advanced stage, and higher number of chemotherapy regimens administered prior to transplantation were adverse prognostic factors for disease progression. We conclude that autologous transplantation is an effective salvage treatment for recurrent HL.
tation; prognostic factors
Hodgkin's lymphoma (HL) is one of the most chemotherapy-responsive malignancies, with an overall long-term disease-control rate of 60-70%. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] However, about onethird of patients suffer progressive disease and require some form of salvage therapy. Patients with limited disease in whom radiation therapy fails can often be successfully treated with chemotherapy. [11] [12] [13] Selected patients with local recurrence after chemotherapy can be successfully treated with radiation therapy. [14] [15] [16] [17] Patients who recur after combination chemotherapy generally have a poor longterm prognosis; few achieve durable disease control. [18] [19] [20] High-dose chemotherapy (HDT) followed by autologous bone marrow (BM) or peripheral blood progenitor cell (PBPC) transplantation is commonly used for treatment of HL after failure of initial systemic chemotherapy treatment. This strategy produces durable remissions in many of these patients. [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] Late relapses, secondary myelodysplasia/ leukemia, and secondary solid tumors may occur, which effects their long-term survival. Selected patients who suffer a relapse after the first transplantation may be salvaged with a second autologous or allogeneic transplantation. We report here the long-term outcome of all patients with induction-refractory or recurrent HL disease who underwent HDT with the CBV regimen, followed by autologous hematopoietic stem cell rescue on consecutive treatment protocols at our institution from 1978 to 1994.
Patients and methods

Eligibility criteria
All patients with induction-refractory or recurrent HL who underwent HDT with a CBV conditioning regimen followed by autologous BM or PBPC transplantation on consecutive treatment protocols between September 1978 and July 1994 at our institution were included in this study. This end-date was selected so that we would have a minimum follow-up time of 8 years for all surviving patients. The date of the last follow-up for patients who were alive at the time of this report was September 2002. Patients whose treatment included a planned tandem transplantation were not included in this analysis.
Patients received therapy on consecutive treatment protocols approved by the institutional review board of The University of Texas M.D. Anderson Cancer Center. Eligibility criteria included: a histological diagnosis of HL, adequate cardiac (left ventricular ejection fraction of X50%), pulmonary (carbon dioxide diffusing capacity of the lung of 450%), hepatic (serum bilirubin p1.0 mg/ 100 ml), and renal (serum creatinine p1.5 mg/100 ml) function. The treatment consisted of cyclophosphamide (1.5 g/m 2 daily for 4 days), BCNU (300 mg/m 2 on day 1 only), and etoposide (150 mg/m 2 every 12 h for four to six doses) followed by autologous PBPC or BM transplantation after a day of rest. Details of the conditioning regimen and supportive care have been described previously. 28 All patients provided written informed consent.
Patients
A total of 184 patients who met the eligibility criteria were treated during the study period. Details of the patient characteristics are given in Table 1 . In all, 117 patients were 
Response definitions
Patients who achieved less than a partial remission (PR) with initial chemotherapy or whose disease progressed despite salvage chemotherapy were considered chemorefractory. PR was defined as a 50% or greater reduction in the sum of the products of the diameters of all measured lesions for at least 4 weeks. Progressive disease was defined as a greater than 25% increase in the sum of the products of the two longest diameters of any measurable lesion or the appearance of (a) new lesion(s). Induction failure was defined as progression during initial therapy or relapse within 8 weeks of completion of initial treatment.
Statistical analysis
Primary end points for the study were overall survival (OS) (time from SCT until death or last follow-up), disease-free survival (DFS) (time from SCT until disease relapse, disease progression, death during remission, or last follow-up), and rate of disease progression (time from SCT until disease progression or relapse). Patients who were alive and in clinical remission were censored at the time of last follow-up. Patients who were lost to follow-up were censored at the time of last follow-up. Cumulative OS and DFS rates were estimated by the Kaplan and Meier method. 39 Risk of disease progression or relapse and nonrelapse mortality (NRM) rates were estimated by the cumulative incidence method. 40 Death in remission was considered a competing risk for the first estimate, and disease relapse or progression for the second. Patients' characteristics according to the year of transplant were compared using the w 2 test. Prognostic factors for disease progression were evaluated by Cox' proportional hazards model 41 on univariate and multivariate analysis. These included chemosensitivity at transplantation, stage, presence of extranodal sites, performance status, presence of B symptoms, LDH levels, albumin levels, age at transplant, number of chemotherapy regimens and radiation treatment prior to transplant, and time from diagnosis to transplant. Some of these factors were highly correlated and the independent effects were evaluated by assessing interactions and confounding. First-order interaction effects were evaluated by creating variables that represent groups of patients who had none, either one or both of the two most significant factors observed on univariate analysis. The additional contribution to the model of the remaining factors significant on univariate analysis was evaluated in order of the strength of the association. Factors with less than 5 patients per category were not considered for multivariate analysis. Statistical significance was defined at 0.05. Analysis was performed using the statistics software package STATA 7.0. 42 
Results
Patient characteristics
The median age of patients undergoing transplantation was 30 years (range, 16-56 years). The reason for transplantation was as follows: failure of induction chemotherapy (Group 1: 46 patients), first relapse or second remission (Group 2: 82 patients), and more advanced relapse or remission (Group 3: 56 patients). In all, 95 patients had received three or more chemotherapy regimens prior to transplantation (median, 3; range, 1-9). In 64 patients, the disease was considered to be refractory to the chemotherapy regimen administered immediately prior to transplantation. A total of 121 patients had received radiation therapy.
Survival analysis
The median follow-up time in patients who were alive at the time of the study was 8.9 years (range, 0.1-19.0 years). At 5 years, the OS and DFS rates were 43% (95% CI 36-50) and 33% (95% CI 26-40), respectively. At 10 years, OS rate was 34% (95% CI 27-42) and DFS rate was 29% (95% CI 22-36) (Figure 1 ). Of the 66 patients who were alive, 53 were continuously disease free, and 13 patients had disease recurrence after transplantation. Six of these 13 patients were in complete remission (CR) after undergoing a second autologous transplant; two patients were in CR after Autologous SCT for HL U Popat et al salvage chemotherapy; one each was alive and in CR after radiation therapy and surgery. The remaining three patients had recurrent active disease. Eight patients suffered relapse X2 years after transplantation, two patients in the third year, three in the fourth year, and one each in fifth, sixth, and seventh year after transplantation.
Nonrelapse mortality
The overall NRM at 100 days after transplantation was 8% (72%). For patients undergoing transplantation before 1990 the 1-year NRM (excluding mortality due to secondary malignancies) was 15% (73%) (18 of 117 patients). For patients who were transplanted between 1990 and 1994, the 1-year NRM was 1.5% (71.5%), (one of 67 patients; the second death was beyond 1 year); (HR 6.5, 95% CI 1.5-28). Since there were only two events between 1990 and 1994, we could not evaluate the risk factors for NRM after adjusting for the year of transplant. However, these differences may be attributed to better patient selection after 1990. Specifically, there were fewer patients with chemorefractory disease, poor performance status, more than three previous chemotherapy regimens prior to transplantation, high LDH, advanced stage, and extranodal disease among the patients treated in the 1990 s (Table 1) . Cumulative incidence of NRM at 3 years (including deaths from secondary malignancies) was 14% (75%), 11% (73%), and 30% (77%) in groups 1, 2, and 3 respectively.
Cause of death
Relapse of HL was the major cause of death after transplantation, resulting in 79 deaths (Table 2 ). A total of 10 patients died of infectious causes (bacterial, two; pneumococcal sepsis at 13 months in a splenectomized patient, one; fungal, three; pneumocystis carinii, three; unknown infection, one; mixed bacterial and fungal infection, one). One patient died of marrow failure, two died secondary to hemorrhagic events, and eight patients had conditioning regimen-related lethal toxicity, mainly pulmonary failure. At the time of this analysis, 19 patients had developed secondary malignancies, five of whom also had recurrent HL. Cumulative incidence of developing a secondary malignancy was 11.5% (73%) at 10 years. The median time to development of secondary malignancy was 42 months (range, 2-157). In total, 12 patients had developed secondary myelodysplasia/leukemia, all of whom died. Seven patients had developed a secondary solid tumor (breast, lung, melanoma, lymphoma, rectal, sarcoma, parotid gland, one each), three of whom died. Three patients died more than 8 years after transplantation, but the cause of death could not be ascertained from the responsible follow-up physician. At the time of the last follow-up, they did not have any signs of recurrent HL or a secondary malignancy.
Prognostic factors
Owing to inherent differences in treatment history by disease status and the small size of each group that limits adjustment, prognostic factors for disease progression were evaluated separately for patients transplanted after induction failure (Group 1, N ¼ 46), after first relapse or in second CR (Group 2, N ¼ 82), and after more advanced relapse or remission (Group 3, N ¼ 56). The results of univariate and multivariate analysis in the three groups are summarized in Tables 3 and 4 .
Induction failure (group 1)
Chemotherapy resistance prior to transplantation, advanced disease stage (XIII), performance status and presence of B symptoms were significant prognostic factors on univariate analysis. The last two factors were highly correlated with disease stage. We evaluated the independent effects of chemotherapy resistance and advanced disease stage by comparing four groups depending on the presence of none, either one or both of these factors. The best outcome was seen in patients with chemosensitive disease and stage I-II disease (N ¼ 9) (HR ¼ 0.2, 95% CI 0.04-0.7), followed by patients who had either one of the unfavorable prognostic factors (N ¼ 19) (HR 0.5, 95% CI 0.2-1.0) in comparison to patients who had both unfavorable factors (N ¼ 18). With a minimum follow-up time of 94 months among patients who are alive in remission, the cumulative incidence of relapse/progression was 22% (713%), 58% (713%) and 67% (714%) respectively in the three groups (Figure 2) . Of the 18 patients, 10 who had chemotherapy resistance and advanced stage disease also had a performance status 41. Poor performance status increased the risk of progression among these patients, although this effect did not reach statistical significance (HR ¼ 2.6, 95% CI 0.8-8.5). The impact of performance status could not be evaluated among the remaining risk groups as only one or two patients in each group had performance status 41. All six patients with B symptoms had advanced disease stage, and the independent effect of this factor could not be assessed. 
First relapse or second CR (group 2)
Factors associated with a significantly higher risk of disease progression on univariate analysis included chemotherapy resistance prior to transplantation, number of chemotherapy regimens received prior to transplantation, prior radiation therapy, presence of extranodal sites, higher disease stage, and transplant before the year 1990. Serum albumin level of X3.5 g/dl had a marginally significant protective effect. Starting with combinations of the two most significant factors on univariate analysis (chemosensitivity and HR ¼ Hazards ratio; NA ¼ not applicable. a There was no difference among patients with three or more prior chemotherapy regimens.
Autologous SCT for HL U Popat et al number of prior chemotherapy regimens), we observed a significantly lower risk of progression among patients with chemosensitive disease who had received less than three chemotherapy regimens prior to transplantation (N ¼ 37) compared to other patients (N ¼ 42), (HR ¼ 0.2, 95% CI 0.1-0.5). The cumulative incidence of relapse/disease progression was (32%78%) and (81%710), respectively ( Figure 3 ). Having received prior radiation did not modify this risk significantly; however, the presence of extranodal sites was independently associated with a two-fold risk (HR ¼ 1.9, 95% CI 1.0-3.5). Disease stage was highly correlated with the presence of extranodal sites (86% of patients with extranodal sites had disease stage XIII); therefore, the independent effects of each factor could not be evaluated. Transplant before 1990 was no longer significant after adjusting for chemosensitivity and number of prior chemotherapy regimens. Albumin level was highly associated with chemosensitivity and number of prior chemotherapy regimens; 31 of 35 patients with chemosensitive disease and less than 3 prior chemotherapy regimens had an albumin level of X3.5 g/dl. Adjustment for confounding was also not possible for this factor. A lower albumin level did not affect the risk of progression among patients with chemorefractory disease who had received X3 prior chemotherapy regimens (HR ¼ 0.6, 95% 0.3-1.3).
Advanced relapse or remission (group 3)
Chemosensitivity was the most significant predictor in this group of patients (HR ¼ 0.2, 95% CI 0.1-0.4). All but one of 12 patients with chemorefractory disease either progressed or died early. Risk factors for progression were therefore evaluated only among patients with chemosensitive disease (N ¼ 35). There was a trend for a higher risk of disease progression among patients who had received X3 chemotherapy regimens and had stage III-IV disease at diagnosis (HR ¼ 2.8, 95% CI 0.8-9.9). None of the remaining factors reached statistical significance.
Risk of progression based on year of transplantation
Year of transplant was one of the factors we evaluated for each disease group. The Kaplan-Meier estimates of the rate of disease progression was 65% for patients transplanted before 1990 and 51% for those transplanted between 1990-1994, (HR 1.8, 95% CI 1.1-2.7). Patients in group 1 had similar rates of disease progression regardless of the timing of transplantation. However, for patients in Groups 2 and 3, the rates of disease progression were lower if transplanted during or after 1990. In group 2 this difference can be explained by the higher number of chemosensitive Autologous SCT for HL U Popat et al patients after 1990. In group 3, 10 of 11 patients who were transplanted during or after 1990 had chemosensitive disease; therefore, the independent effects of chemosensitivity and the year of transplantation on disease progression could not be evaluated.
Second transplantation
In total, 25 patients whose disease progressed after CBV underwent a second transplant, 22 for recurrent or progressive HL, and three for secondary myelodysplasia/ leukemia. Six of the 22 patients who underwent a second autologous transplantation for recurrent disease were alive and in continuous remission at a median follow-up of 42 months (range, 20-84 months) after transplantation. The remaining patients died.
Discussion
This study confirms that autologous hematopoietic stem cell transplantation can result in durable long-term remissions in a significant proportion of patients with HL otherwise deemed incurable with conventional chemotherapy. [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] In the present study (median follow-up of 8.9 years) we evaluated various disease, patient and transplantrelated factors for outcome with autologous transplantation. Various factors have been reported to influence the outcome after HDT and autologous transplantation for HL. These include performance status, 21, 23, 31 number of prior chemotherapy regimens, [21] [22] [23] [24] 27, 30, 33 the presence of bulky disease, 27 ,34 the length of initial remission, 29 the presence of extranodal disease, [29] [30] [31] clinical stage, 28 the presence of B symptoms at the time of transplantation, 22, 28, 29 and sensitivity to conventional chemotherapy. 22, 33, 35, 36 However, many of these factors are highly correlated and the independent effects of each may be difficult to evaluate. Therefore, several authors have created models that identify a combination of risk factors. 28, 29, 43 A study from Vancouver identified that systemic symptoms at relapse, extranodal disease at relapse and initial CR of o12 months were significant factors affecting PFS. The actuarial 3-year PFS was 100, 81, 40, and 0% for patients with 0, 1, 2, or 3 risk factors respectively. 29 In the present study univariate analysis (Table 3) identified chemotherapy resistance prior to transplantation and advanced disease stage at diagnosis (stage XIII) to be associated with a higher risk of disease progression after transplantation. Other factors that were significant in predicting the outcome after autologous transplantation included performance status, number of chemotherapy regimens received prior to transplantation, presence of extranodal sites of disease, and B symptoms.
On multivariate analysis (Table 4 ) chemosensitivity of the disease along with number of prior chemotherapy regimens, disease stage and extranodal disease remained important prognostic variables in predicting the progression-free survival after autologous transplantation for refractory or recurrent HL. Among the patients transplanted for induction failure, the best outcome was seen in patients who had early stage chemotherapy sensitive disease and the worst outcome was seen in patients with advanced stage chemorefractory disease. Andre et al 25 also reported that the response to salvage chemotherapy administered prior to transplantation was a significant prognostic factor for survival after autologous transplantation in patients with primary induction failure. 25 For patients undergoing transplantation after first relapse or in second CR, the most significant predictor of disease progression after transplantation was chemosensitive disease and having received less than three chemotherapy regimens prior to transplantation. Others have also reported that chemotherapy resistance prior to autologous transplantation has a significant negative influence on the post transplant DFS. 35, 36 The DFS rates for patients who undergo transplantation for a second or subsequent relapse have varied in the literature, with some studies showing a better outcome and others showing a worse outcome for these patients than for those undergoing transplantation at the time of first relapse. 27, 31, [44] [45] [46] Our analysis indicated a high failure rate in this subgroup due to a higher number of nonrelapserelated deaths stemming from regimen-related toxicity and secondary malignancies. Therefore, to make the transplant procedure optimally safe with low treatment-related toxicity, while decreasing the risk for secondary malignancies, it may be prudent to perform the transplant at the time of first relapse rather than at a later stage of the disease.
Over the period of our study, there was a significant decrease in the TRM in our HL patients treated with HDT. In fact, in the last 5 years of this study we had only one treatment-related death among the 67 treated patients (o2%). There was clearly an improved treatment outcome for patients transplanted in the 1990s. There was a lower rate of relapse after 1989, for patients transplanted in first relapse or after a second remission in our study. This effect was attributed to chemosensitivity in multivariate analysis. The importance of chemosensitivity was corroborated by the observation of no change in the relapse rate over time for patients transplanted after primary induction failure. Of 11 patients with advanced disease stage who received a transplant after 1989, 10 were chemosensitive, so the independent effect of chemosensitivity could not be evaluated in this group. Similar observations have been made by other authors as well. 35, 36 The reasons for this could be multifactorial, but patient selection criteria seem to be the most important factor ( Table 1 ). The respective effects of PBPC vs BM as the source of stem cells, and the impact of growth factor support on disease progression could not be ascertained in the present study as availability of these drugs in the later years of the study period coincided with better patient selection.
Of concern are the late relapses after autologous transplantation for HL that have been described. 21, 37 In the present study that spanned almost 24 years, we observed eight relapses beyond the second year after transplantation. It was fatal in six of the patients.
Second malignancies after the successful treatment of HL has been observed in both transplant 28, 29, 47 and nontransplant [48] [49] [50] [51] setting. All 12 patients in our study who developed secondary myelodysplasia/leukemia died. Others have also reported a poor outcome in this subgroup of patients, despite aggressive therapy, in some instances including allogeneic transplantation. 52 It draws attention to the fact that, although HDT may confer long-term disease control in a proportion of patients otherwise deemed incurable, the potential for it to induce a second malignancy needs to be addressed.
In conclusion, HDT is an effective salvage therapy for relapsed and recurrent HL. Over the past decade, the outcome in these patients has improved, in part due to better patient selection. Specifically, patients who undergo transplantation before failing multiple chemotherapy regimens, and who have chemosensitive disease have a better outcome. A different therapeutic approach is needed for patients with extensive, chemorefractory disease. A further concern that needs to be addressed is that some patients may develop late relapses or a secondary malignancy, affecting the overall chance for long-term survival.
